Peihong Wu
    Title Professor

    Dr. Peihong Wu, is a professor of Sun Yat-sen University, visiting professor of School of Medicine University of Rochester, USA, and visiting professor of School of Medicine University of Toronto, Canada. He is also the president of the Society of Minimally Invasive Therapy in Oncology, Chinese Anti-Cancer Association; and the director of the Department of Medical Image and Image Guided Therapy, Sun Yat-sen University Cancer Center.He has published 6 books, more than 130 papers in non-SCI journals and 40 peer-reviewed papers on image diagnosis and image-guided therapy in oncology. 

    1995-1998 Associate Professor and Vice Director, Department of Medical Image and Image Guided Therapy

    1998-present Director and Professor of the Department of Medical Image and Image Guided Therapy, Sun Yat-sen University Cancer Center

    1999-2000 Visiting scholar. Interventional Radiology and Imaging Diagnosis MD Anderson Cancer Center 

    2001-present Member of Standing Committee of Interventional Therapy on Oncology, Chinese Anti-Cancer Association

    2006-present President of the Society of Minimally Invasive Therapy in Oncology, Chinese Anti-Cancer Association2007-present Chairman of the Committee of Minimally Invasive Therapy and Integrated Therapy for Hepatocellular Carcinoma, Chinese Anti-Cancer Association

    2007-present Member of Standing Committee of Chinese Anti-Cancer Association

    2010-present Member of Academic Committee Sun Yat-sen University Cancer Center

    2010-present Member of Medical Quality Management Committee Sun Yat-sen University Cancer Center

    2013-present Award of TOP10DR in interventional radiology in China

    2014-present Award of the most outstanding doctors in Sun Yat-sen University

    2014-present Member of Board Director of Asian Tumor Ablation Association

    2014-present Executive Member of Board Director of Asian Pacific Image-guided Therapy Association.

    Research Interest(s)

    1. Combination of image-guided minimally invasive therapy with chemotherapy, radiotherapy and surgery.

    2. Image-guided minimally invasive therapy combined with bio-immunotherapy.

    3. Constructive model and strategy for cancer treatment: at the basis of effective elimination of malignant tumor, maximize the physical function, immunity and life quality of patients.


    1982 M.D. Sun Yat-sen University, Guangzhou, China

    1982-1985 Resident, Radiology and Clinical Oncology 

    1985-1988 Fellow, Radiology and Interventional Radiology 

    1988-1995 Attending Doctor, Department of Radiology and Interventional Radiology

    Huang Jinhua
    Title Professor, advisor of master’s degree student

    Prof. Huang Jinhua has engaged himself in professional clinical practice for over 20 years, accumulated abundant experience in interventional treatment and minimally invasive surgery for cancer and is proficient in curing cancers with various technologies of minimally invasive surgery and treatment. The primary interventional treatment technologies and the cancers cured include: 1. transarterial chemoembolization of liver cancer; 2. transarterial infusion of cancer; 3. ablation of liver cancer, lung cancer, kidney cancer and other solid tumors with radiofrequency and ablation; 4. comprehensive interventional and minimally invasive treatment for gynecologic refractory tumors; 5. implantation of radioactive particles into tumors; 6. (esophageal stricture, obstruction of biliary tract and venous stenosis) endovascular stent implantation.

    Research Interest(s)     

    1985: Graduated from School of Medicine, Medical College of Nanchang University (undergraduate)

    1992: Obtained a master’s degree from Shanghai Jiao Tong University School of Medicine (SJTUSM)

    2003 – 2004: Studied in MD Anderson Cancer Center, US



    1. Radioablation settings affecting the size of lesions created ex vivo in porcine livers with monopolar perfusion electrodes. Acad Radiol 2010;17(8): 980-984.

    2. Transarterial embolization ablation of hepatocellular carcinoma with a lipiodol-ethanol mixture. World J Gastroenterol 2010;16(45): 5766-5772.

    3. CT, MRI, and FDG-PET/CT imaging findings of abdominopelvic desmoplastic small round cell tumors: Correlation with histopathologic findings. Eur J Radiol 2010.

    4. Combined treatment of hepatocellular carcinoma with partial splenic embolization and transcatheter hepatic arterial chemoembolization. World J Gastroenterol 2007,13(48):6593-6597.


    Zhang Fujun
    Title Professor and Chief Physician
    Dr. Zhang is a professor and deputy director of the Institute of Medical Imagingand Interventional Radiology. Dr. Zhang obtained his Bachelor in Medicine (equivalent to MD in theUS) at Bethune Medical University and PhD at the Second Military Medical University, China in 1997 and 2006, respectively. As a visiting scholar, he learned at the MolecularI maging Research Center, Baylor College of Medicine, USA in 2008. He specializes in minimally invasive treatment of cancer (liver cancer, lung cancer and other solid tumors) and molecular imaging diagnosis and treatment. He took the lead to carry out the tumor ablation (RFA, PMCT, Cryoablation) and radioactive iodine-125 brachy therapy in China. He presided over a number of national and provincial research projects. Recent years, as the first author and corresponding author, he has published more than 70 research papers (including Oncotarget, BBA-Gene Regulatory Mechanisms, etc.) and edited several books.
    Research Interest(s) Minimally invasive treatment of cancer (liver cancer, lung cancer and other solid tumors) and molecular imaging diagnosis and treatment.

    1987: Graduated from undergraduate medical program at Inner Mongolia Medical University.

    1997: Obtained a master’s degree in medical imaging and nuclear medicine from Norman Bethune College of Medicine Jilin University.

    2006: Obtained a doctoral degree in medical imaging and nuclear medicine from Second Military Medical University

    09/2008-12/2008: Acted as a visiting scholar in the Department of Radiology, U.S. Baylor College of Medicine


    1.Osteosarcoma:Limb salvaging treatment by ultrasonogrphically guided high intensity focused ultrasound.CancerBiolTher 2009;(12)1102-1108

    2.Superficial malignant tumors:Non-invasive treatment with ultrasonographically guided high-Intensity focused ultrasound.CancerBiolTher 2009;8(24)(December15;2009)

    3.Short to mid term evaluation of CT-guided I125 brachytherapy on intra-hepatic recurrent tumors and/or extra-hepatic metastases after liver transplantation for hepatocellular carcinoma.CancerBiol Ther.2009;8(7):585-590

    4. Feasibility of 125I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology. 2010 Nov;136(11):1633-40

    5. Noninvasive treatment of malignant bone tumors using high-intensity focused ultrasound.Cancer. 2010 Aug 15;116(16):3934-42.

    6. Therapeutic effects and prognostic factors in high-intensity focused ultrasound combined with chemoembolisation for larger hepatocellular carcinoma. European Journal Cancer. 2010 Sep;46(13):2513-21

    7. Microwave ablation treatment of liver cancer with 2,450-MHz cooled-shaft antenna: an experimental and clinical study.Journal of Cancer Research and Clinical Oncology. 2010 Oct;136(10):1507-16

    8. An imageable retinoid acid derivative to detect human cancer xenografts and study therapeutic dosing to reduce its toxicity.Contrast Media Mol Imaging. 2010 Nov 30. [Epub ahead of print]

    9. Computed tomography and magnetic resonance imaging findings of peripheral primitive neuroectodermal tumors of the head and neck. European Journal of Radiology. 2011 Feb [Epub ahead of print]

    10. Ke, S. and F. Zhang, et al. (2012). "Multiple target-specific molecular imaging agents detect liver cancer in a preclinical model." CurrMol Med 12 (8): 944-51.

    11.Hu, X. and H. Qiu, et al. (2012). "Recurrent gliomas: comparison of computed tomography (CT)-guided 125I seed implantation therapy and traditional radiochemotherapy." Cancer BiolTher 13 (10): 840-7.

    12. Peng, S. and Q. X. Yang, et al. (2014). "Lobaplatin-TACE combined with radioactive 125I seed implantation for treatment of primary hepatocellular carcinoma." Asian Pac J Cancer Prev 15 (13): 5155-60.

    13. Yang, G. and S. Zhang, et al. (2014). "Osteopontin enhances the expression of HOTAIR in cancer cells via IRF1." Biochim Biophys Acta 1839 (9): 837-48.

    14. Yang, G. and S. Zhang, et al. (2014). "The inhibitory effects of extracellular ATP on the growth of nasopharyngeal carcinoma cells via P2Y2 receptor and osteopontin." J Exp Clin Cancer Res 33: 53.

    15. Zhang, T. and M. Lu, et al. (2014). "CT-guided implantation of radioactive 125I seed in advanced non-small-cell lung cancer after failure of first-line chemotherapy." J Cancer Res Clin Oncol 140 (8): 1383-90.

    16. Yang, G. and S. Peng, et al. (2014). "Cell-based assay system to estimate the effect of 125I seeds on cancer cells: effect of osteopontin." Recent Pat Anticancer Drug Discov 9 (2): 258-63.

    17. Zhang, W. and Y. Zhang, et al. (2014). "Multi-modality imaging to determine the cellular heterogeneity of nasopharyngeal  carcinoma components." Oncotarget 5 (8): 2221-9.

    18. Liu, Z. and F. Gao, et al. (2014). "Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis." Tumour Biol.

    Fan Weijun
    Title Professor

    Professor Weijun Fan is currently deputy director of Department of Minimally Invasive Interventional Therapy at Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China.  As the leader of the First Tumor Ablation Training Course of the Chinese Medical Doctor Association (CMDA), professor Fan has pioneered the Chinese Medical Doctor Association's tumor ablation training. So far, the Training Course has trained more than 5,000 ablation professionals for all provinces and municipalities across the country. As the leader of the tumor ablation training expert group, he participated in the organization of 29 sessions of ablation training, and organized the compilation of the first set of tumor ablation training materials of the CMDA, which has made great contributions to the cause of tumor ablation in China. Professor Fan Weijun edited the first monograph on microwave ablation of tumors called “Microwave Ablation Therapy for Tumors”, which laid the foundation for the popularization of tumor microwave ablation technology in China. Moreover, he organized the "Expert Consensus for Thermal Ablation for Primary and Metastatic Lung Tumors" and "Expert Consensus for Image-guided Adrenal Tumor Ablation Treatment".  

    Professor Fan is currently the chairman of the ablation committee of the CMDA intervention branch; the leader of the tumor ablation treatment technology expert group of the CMDA; the candidate of the chairman of the professional committee member of the tumor ablation treatment of the CHINESE ANTI CANCER ASSOCIATION (CACA); Deputy Director of the Tumor Ablation Therapy Expert Committee of the Chinese Society of Clinical Oncology (CSCO); Chairman of the Respiratory Intervention Special Committee of the Interventional Group of the Chinese Society of Radiology (CSR); the candidate of the chairman of the Professional Committee of Tumor Minimally Invasive Therapy of Guangdong Anticancer Association. Besides, Professor Fan is the Chinese deputy Editor-in-Chief of “Journal of Cancer Research and Therapeutics”. And he also is the editorial board member of "Interventional Radiology" and "Anatomy and Clinical Medicine". At present, he has published fifties of papers.

    Research Interest(s)
    The minimally invasive interventional therapy ofvarieties of Solid Tumor, especially Hepatocellular Carcinoma and MalignantMelanoma. 

    More than fifty papers were published in core Journals in China, and more than twenty SCI papers were published on multiple magazines, such as Cancer, Aging, Cancer Immunology Immunotherapy, International Journal of Hyperthermia, AJR, and JVIR.

    1. Xin Li, Weijun Fan, Liang Zhang, Ming Zhao, Zilin Huang, Wang Li, Yangkui Gu, Fei Gao, Jinhua Huang, Chuanxing Li, Fujun Zhang, Peihong Wu, CT-Guided Percutaneous Microwave Ablation of Adrenal Malignant Carcinoma, Cancer,2011.11.15,117(22):5182~5188

    2. Cao F, Shen L, Qi H, Xie L, Song Z, Chen S, Fan W: Tree-based classification system incorporating the HVTT-PVTT score for personalized management of hepatocellular carcinoma patients with macroscopic vascular invasion. Aging (Albany NY) 2019, 11(21):9544-9555. 

    3. Shen L, Qi H, Chen S, Cao F, Xie L, Wu Y, Ma W, Song Z, Yuan H, Zhang T, Li D, Wen X, Chen Q, Li W, Zhang X, Fan W. Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study. Cancer Immunol Immunother. 2020. doi: 10.1007/s00262-020-02566-z.

    4. Fan WeiJun, Li Xin, Zhang Liang, Jiang Hua, Zhang JianLei, Comparison of Microwave Ablation and Multipolar Radiofrequency Ablation In Vivo Using Two Internally Cooled Probes, American Journal of Roentgenology, 2012.1.01,198(1):W46~W50

    5. Li Xin, Zhang Liang, Fan Weijun, Zhao Ming, Wang Ligang, Tang Tian, Jiang Hua, Zhang Jianlei, Liu Yanfeng, Comparison of microwave ablation and multipolar radiofrequency ablation, both using a pair of internally cooled interstitial applicators: Results in ex vivo porcine livers, INTERNATIONAL JOURNAL OF HYPERTHERMIA,2011.01.01, 27(3):240~248

    6. Xie L, Cao F, Qi H, Song Z, Shen L, Chen S, Hu Y, Chen C, Fan W: Efficacy and safety of CT-guided percutaneous thermal ablation for hepatocellular carcinoma adjacent to the second porta hepatis. Int J Hyperthermia 2019, 36(1):1122-1128.

    7. Chen S, Shi M, Shen L, Qi H, Wan W, Cao F, Xie L, Wu Y, Chen G, Mo J, Zhu G, Ye D, Zhang Y, Feng Z, Xu L, Fan W: Microwave ablation versus sorafenib for intermediate-Stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis. Int J Hyperthermia 2020, 37(1):384-391.

    8. Li Xin, Fan Weijun, Zhang Liang, Zhang Xiao-ping, Jiang Hua. Zhang  Jian-lei, Zhang Hao, CT-guided Percutaneous Microwave Ablation of Liver Metastases from Nasopharyngeal Carcinoma, JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2013.5.01, 24(5):680~684

    9. Qiuxia Yang, Han Qi, Rong Zhang, Chao Wan, Ze Song, Liang Zhang, Weijun Fan. Risk Factors for Local Progression after Percutaneous Radiofrequency Ablation of Lung Tumors: Evaluation Based on a Review of 147 Tumors, J Vasc Interv Radiol,2017.01.19

    10. Qi H, Fan W. Value of ablation therapy in the treatment of lung metastases. Thoracic Cancer. 2017 doi:10.1111/1759-7714.12567

    11. Cao F, Xie L, Qi H, Chen S, Shen L, Song Z, Fan W: Safety and efficacy of thermal ablation for subpleural lung cancers. THORAC CANCER 2019, 10(6):1340-1347.

    12. Cao F, Wan C, Xie L, Qi H, Shen L, Chen S, Song Z, Fan W: Localized RNA interference therapy to eliminate residual lung cancer after incomplete microwave ablation. THORAC CANCER 2019, 10(6):1369-1377.

    13. Qiu Z, Shen L, Chen S, Qi H, Cao F, Xie L, Fan W: Efficacy Of Apatinib In Transcatheter Arterial Chemoembolization (TACE) Refractory Intermediate And Advanced-Stage Hepatocellular carcinoma A Propensity Score Matching Analysis. CANCER MANAG RES 2019, 11:9321-9330.

    Updated April 2021

    Zhao Ming
    Title Chief physician, advisor of master’s degree student

    Zhao Ming was appointed as the associate chief physician, associate professor and advisor of master’s degree student at Sun Yat-sen University Cancer Center. He is familiar with human imaging anatomy and imaging vascular anatomy and proficient in interventional diagnosis and treatment for solid tumors, such as interventional chemoembolization and radiofrequency ablation of primary liver cancer and metastatic colorectal cancer, integrated application of molecular targeted therapy, radiofrequency ablation of lung cancer and lung metastatic tumors and integrated application of TACE, TAI and molecular targeted therapy; palliative treatment for advanced tumors, such as drainage of and stent implantation of obstructive jaundice, stent implantation in the esophagus, stent implantation in the vena cava, image-guided implantation of radioactive particles under, nerve compression and interventional treatment for pain palliation of metastatic bone tumors. He is able to grasp the developments in cancer treatment and provide out-patient medical advice and popularization of science, and attends clinical and multidisciplinary consultations on hepatobiliary diseases for chief scientists. With regard to single diseases, he owns an in-depth research on and abundant clinical experience in hepatic metastases, which he also regards as his basis for research.

    Research Interest(s)

    Guided by the concept of single disease sand multidisciplinary integrated treatment, he systematically carries out clinical research on liver tumors and solid tumors in the lung and gradually implements the concept of integrating interventional treatment and minimally invasive surgery planning system into individualized treatment; conducts real-time ablation treatment for tumors under the guidance of MRI and performs local treatment for such solid cancers as liver cancer, lung cancer and retroperitoneal cancer with various means of minimally invasive surgery including nano-knife. Taking prolong survival as the goal, he analyzes factors concerning the systemic immunity of tumors’ recurrence and gradually takes measures of intervention clinical treatment by studying immune regulation of recurrent primary liver cancer and its immune tolerance mechanism.


    January 2014: appointed as the Chief Physician of Sun Yat-sen University Cancer Center;
    April 2011-September 2013: studied at Brigham and Women’s Hospital, Harvard University and worked on medical research on basis for immunology and transformation of tumors;

    September 2008: short-term study in Barcelona Clinic Liver Cancer (BCLC);
    2002-2006: Studied interventional treatment and minimally invasive surgery for liver cancer and obtained the doctoral degree in oncology;

    1997-2000: received specialist training of cancer and obtained a master’s degree in oncology from Sun Yat-sen University (former Sun Yat-sen University of Medical Sciences);

    1993-1997: completed clinical training for resident physicians at the First Affiliated Hospital of Bengbu Medical College



    1. Percutaneous CT-guided radiofrequency ablation as supplemental therapy after systemic chemotherapy for selected advanced non-small cell lung cancers. Am J Roentgenol.2013;201(6):1362-7.

    2. Transcriptomic profiling of Aspergillusflavus in response to 5-azacytidine. Fungal Genet Biol. 2013;56:78-86.

    3. Chromosomal evolution of Escherichia coli for the efficient production of lycopene. BMC Biotechnol 2013;13(1):6.

    4. Percutaneous CT-guided radiofrequency ablation for unresectable hepatocellular carcinoma pulmonary metastases. International Journal of Hyperthermia 2012;28:721-728.

    5. CT-guided radiofrequency ablation after with transarterial chemoembolization in treating unresectable hepatocellular carcinoma with long overall survival improvement. Eur J Radiol 2012;81(10):2717-2725.

    6. Comparative survival analysis in patients with pulmonary metastases from nasopharyngeal carcinoma treated with radiofrequency ablation. Eur J Radiol 2012;81(4):e473-e477.

    7. Retroperitoneal schwannoma treated with percutaneous computed tomography-guided radiofrequency ablation. J Neurosurg Spine 2012;17(2):173-176.

    8. Challenges in the modification of the M1 stage of the TNM staging system for nasopharyngeal carcinoma: A study of 1027 cases and review of the literature. Exp Ther Med 2012; 4:334-338

    9. CT-guided radiofrequency ablation prolonged metastatic survival in patients with liver metastases from nasopharyngeal carcinoma. Int J Hyperthermia 2011; 27(6):549-554.

    10. Huge refractory retroperitoneal nerve sheath tumor treated with radiofrequency ablation: a case report with literature review. Chin J Cancer 2010; 29(4):463-6.

    Fei Gao
    Title Associate Professor
    Dr. Fei Gao is associate professor of Medical Imaging and Interventional Radiology. He obtained his Ph.D. at Sun Yat-sen University Cancer Center, P. R. China in 2012. His postdoctoral training at University of Rochester University Medical Center provided him with great opportunities to explore the fields of Y90 treatment for HCC, TIPS and solid tumor ablations guided by TPS. Dr. Gao has published more than 10 research papers.
    Research Interest(s)

    1.Microwave ablation for solid tumors.

    2.Study on the advantage of treatment for hepatic carcinoma with hypersplenism by TACE combined with splenic microwave ablation.

    3.Biliary stents placement


    6/20/2003 Bachelor of Medical ImagingSun Yat-sen UniversityGuangzhou, China

    6/22/2009 Master of Medical ImagingSun Yat-sen University Guangzhou, China

    6/26/2012 M.D. of Oncology,Sun Yat-sen University Guangzhou, China


    1. Gao F, Gu YK, Huang JH, Zhao M, Wu PH. Radiofrequency Ablation of Retroperitoneal Metastatic Lymph Nodes from Hepatocellular Carcinoma Acad Radiol 2012;19:1035-1040. 

    2. Gao F, Li CX, Gu YK, Huang JH, Zhang FJ, Wu PH. CT-guided 125I brachytherapy for Mediastinal Metastatic Lymph Nodes Recurrence from Esophageal Carcinoma: Effectiveness and Safety in 16 Patients. Eur J Radiol 2013;82:e70-e75.

    3. Gao F, Gu YK, Fan WJ, Zhang L, Huang JH. Evaluation of transarterial chemoembolization combined with percutaneous ethanol ablation for large hepatocellular carcinoma.World J Gastroenterol 2011; 26:3145-3150. 

    4. Gao F, Gu YK, Shen JX, Li CL, Jiang XY, Huang JH. Experimental study of destruction to porcine spleen in vivo by microwave ablation.World J Gastroenterol. 2011;45:5014-5020. 

    5. Gao F, Zhong R, Li GH, Zhang WD. Computed tomography and magnetic resonance imaging findings of inflammatory myofibroblastic tumors of the head and neck. Acta Radiol. 2013 Aug 21. [Epub ahead of print] 

    6. Jingxian Shen, Fei Gao*, Jing Zhao, Yunxian Mo, Peihong Wu. Small hepatocellular carcinoma keeping hypodense during dual phase helical CT scan and correlative pathology. J Biomed Graph Comput 2013;3:1-7. (* Corresponding author)

    7. Yongxin Chen, Fei Gao*, Lin Chen, Sheng Peng, Yingjie Huang, Yao Wang. Effectiveness and Safety of CT-Guided 125I Brachytherapy for Lung Metastasis from Hepatocellular Carcinoma. Open Journal of Radiology 2013;3:159-164. (* Corresponding author)

    8. Luo RG, Gao F, Gu YK, Huang JH, Li CL. Radioablation settings affecting the size of lesions created ex vivo in porcine livers with monopolar perfusion electrodes.Acad Radiol 2010;8:980-984. 

    9. Luo RG, Gao F, Huang JH, Jiang XY, Huang YJ. Experimental study on diluted hydrochloric acid enlarging radiofrequency ablation lesions in excised porcine livers. Diagnostic and Interventional Radiology 2012. doi:10.4261 /1305-3825. DIR. 6093-12.1. 

    10. Huang JH, Gao F, Gu YK, Li WQ, Lu LW. Combined treatment of hepatocellular carcinoma with partial splenic embolization and transcatheter hepatic arterial chemoembolization. World J Gastroenterology 2007; 48:6593-6597.

    Huang Zilin
    Title Associate chief physician
    Dr. Huang Zilin graduated from the Department of Clinical Medicine, Sun Yat-sen University of Medical Sciences (6-year undergraduate program) in 1991. Currently, he serves as the associate chief physician at the Department of Imaging and Minimally Invasive Surgery, Sun Yat-sen University Cancer Center, and engages himself in imaging diagnosis and MIS and intervention treatment of tumors. His Research Interests includes image-guided ablation of cancer with radiofrequency and microwave, cryotherapy with argon-helium knife, implantation of radioactive particles into tumors, vascular interventional treatment of tumors; indications of MIS of tumors, appropriate selection and application of methods and treatment of complications.
    Research Interest(s)
    Gu Yangkui
    Title Associate chief physician

    Dr. Gu Yangkui graduated from Sun Yat-sen University of Medical Sciences in 1998 and has worked in the University after obtaining a master’s degree from Sun Yat-sen University in 2002. She completed the training for resident doctors and chief physician at Sun Yat-sen University Cancer Center and was promoted as Associate chief physician in December 2010.

    Dr. Gu Yangkui possesses rich clinical experience in minimally invasive surgery of primary liver cancer and colorectal liver metastases and specializes in ablation of liver cancer and stent implantation of various stenosis.

    Research Interest(s) Biological basis and individualized treatment for molecules concerning colorectal liver metastases
    Lujun Shen
    Title Associate chief physician
    Dr. Lujun Shen completed M.D. degree of clinical medicine (8-year program) in Sun Yat-sen University (China) in 2015. He is working in the department of minimally invasive therapy, Sun Yat-sen University Cancer Center. Through his M.D. study at Sun Yat-sen University and thereafter, he have been doing research in the fields of “developing novel methodology and computational tools for cancer prognosis prediction” and “Minimally invasive interventional therapies for cancer”, with a series of research published in the past 5 years as first author, including in Nature Communications, Radiology, Cancers, etc. 
    Research Interest(s)

    1. Dynamic prognostication and treatment of cancer using big data. 

    2. Enhancing efficacy of immunotherapy through local modulation.


    Sun Yat-sen University (SYSU), Major GPA: 3.6/5.0      

    Sept. 2007-July, 2015 Clinical Medicine (8-year-program)


    1.Shen L#,Chen Q#, Yang C#, Wu Y#, Yuan H, Chen S, Ou S, Jiang Y, Huang T, Ke L,Mo J,Feng Z, Zhou P, Fan W. Role of PRDM1 in Tumor Immunity and Drug Response: APan-Cancer Analysis. FrontPharmacol. 2020 Dec 15;11:593195.

    2.Shen L#,Qi H#, Chen S#, Cao F#, Xie L, Wu Y, Ma W, Song Z, Yuan H, Zhang T, Li D, WenX, Chen Q, Li W, Zhang X, Fan W. Cryoablation combined with transarterialinfusion of pembrolizumab (CATAP) for liver metastases of melanoma: anambispective, proof-of-concept cohort study. CancerImmunol Immunother. 2020 Sep;69(9):1713-1724.

    3. Shen L,Chen S, Qiu Z, Qi H, Yuan H, Cao F, Xie L, Chen Q, Li W, Fan W. Transarterialchemoembolization combined with apatinib versus transarterial chemoembolizationalone for hepatocellular carcinoma with macroscopic vascular invasion: Apropensity score matching analysis. JCancer Res Ther. 2020 Sep;16(5):1063-1068. doi:10.4103/jcrt.JCRT_801_19.

    4.Shen L#,Zeng Q#, Guo P#, Huang J#, Li C, Pan T, Chang B, Wu N, Yang L, Chen Q, Huang T,Li W*, Wu P*. Dynamically prognosticating patients with hepatocellularcarcinoma through survival paths mapping based on time-series data. Nat Commun. 2018 Jun 8;9(1):2230

    5.Shen L#,Xi M#, Zhao L, Zhang X, Wang X, Huang Z, Chen Q, Zhang T, Shen J, Liu M, HuangJ. Combination Therapy after TACE for Hepatocellular Carcinoma with MacroscopicVascular Invasion: Stereotactic Body Radiotherapy versus Sorafenib. Cancers (Basel). 2018 Dec14;10(12).

    6.Shen LJ#,Wang L#, Wang SY, Xie GF, Zeng Q, Shi F, Zhang Y, Wu M, Shu WH, Pan CC, Xia YF,Wu PH*. Imaging-based multi-level subdivision of M1 category in TNM stagingsystem for metastatic nasopharyngeal carcinoma. Radiology.2016 Sep; 280(3):805-14

    Updated November 2021

Where are we | Contact us|

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.